##  [Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS](/us-en/news/media-releases/novartis-multiple-sclerosis-therapy-fingolimod-granted-fda-breakthrough-therapy-designation-pediatric-ms-0 "Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS") 

  Dec 18, 2017